tailieunhanh - báo cáo khoa học: "Journal of hematology & oncology: A journal open to all Delong Liu"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Journal of hematology & oncology: A journal open to all Delong Liu | BioMed Central Journal of Hematology Oncology Editorial Journal of hematology oncology A journal open to all Delong Liu Open Access Address Associate Professor of Medicine New York Medical College Munger Pavilion 250 Valhalla NY 10595 USA Email Delong Liu - delong_liu@ Published 28 May 2008 Received 23 May 2008 Journal of Hematology Oncology 2008 1 1 doi 1756-8722-1 -1 Accepted 28 May 2008 This article is available from http content 1 1 1 2008 Liu licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Editorial Paul Ehrlich prophesied magic bullet in early 1900 1 but it was not until 1975 that Kohler and Milstein developed the hybridoma technology 2 . Since then hematology and oncology have become closely intertwined and rapidly evolving fields. New findings from laboratorybased research are rapidly being turned into clinical applications. Within less than a decade targeted therapy has become a treatment of choice for many diseases with imatinib and rituximab representing the many recent major breakthroughs in cancer therapy 3 4 . The growth of the internet has shrunk the world to a mouse click yet the dissemination of new scientific findings is still very restricted. As a scientist and a clinician I have to squeeze out time to publish new scientific findings and clinical observations. It almost always takes months to get a manuscript published. Frequently the published articles are accessible only to those with subscriptions. Journal of Hematology Oncology aims to serve as an international platform for sharing laboratory and clinical findings in an open access format among laboratory scientists physician scientists hematologists and oncologists. A rapid turnaround time from submission to .